Trials & Filings

Gilead’s Stribild Posts Three-Year HIV-1 Results

Favorable data against Atripla and protease inhibitor plus Truvada

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Gilead Sciences has posted three-year (144-week) efficacy and safety results from two pivotal Phase III studies (Studies 102 and 103) evaluating the once-daily single tablet regimen combination drug Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) among treatment-naïve patients with HIV-1 infection. Data show that after three years of treatment, Stribild demonstrated comparable efficacy to two standard-of-care HIV regimens, Atripla (efav...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters